Hemorai is a company focused on developing innovative biomedical devices and technologies. One of their key offerings is the coherent spatial imaging (CSI) system, which combines optical property measurements from spatially-resolved diffuse reflectance spectroscopy (srDRS) with speckle pattern-based blood flow measurements. This CSI technique enables high-speed measurements of speckle contrast and diffuse reflectance, providing critical information to assess absolute measurements of pulsatile blood flow, blood volume, oxygen saturation (stO2), and tissue metabolic rate of oxygen (tMRO2).
The CSI system utilizes miniaturized optoelectronic components to map radially-varying diffuse reflectance of coherent light from tissues, allowing for absolute measurement of absorption and scattering contrast. This technology has the potential to measure hemodynamic dysfunction that is expected to occur during early stages of hemorrhage, as the supply and utilization of oxygen can become decoupled in abnormal physiological states.
Hemorai's team consists of experts in various fields, including mechanical engineering, electrical engineering, biomedical optics, and laser surgery research. They have experience in designing and prototyping biomedical devices, developing functional materials for additive manufacturing, creating bench-top and catheter systems for image-guided surgery, and working on precision in vivo laser surgery for brain cancer utilizing optical coherence tomography (OCT).
The company has built upon the CSI technology originally developed by the University of California, Irvine (UCI), improving and refining it for practical applications.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.